Clinical trial information

Registration Item	Details of registration Item	Contents
Title of the study	Title of the study	A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with Alzheimer's Disease.
	Primary sponsor	Toyama Chemical Co., Ltd
	Study Type	interventional (treatment)
	Summary	To evaluate the efficacy of T-817MA in patients with mild to moderate Alzheimer's Disease
Details of study	Interventional drug name	T-817MA
	Target illness	Alzheimer's Disease
	Classification name (code) of the investigational drug	119 (other agents affecting central nervous system)
	Administration route	oral
	Control drug name(code/td)	placebo
	Classification name (code) of the investigational drug	-
	Administration route	oral
	Objectives of the study	medical treatment
	Study phase	Phase 2
	Study design	double-blind
	Inclusion Criteria	Patients, whose age is between 55 and 90, taking donepezil hydrochloride, and diagnosed as mild to moderate Alzheimer's Disease according to the diagnostic criteria Age: 55 to 90 Sex: Both
	Outcome	Efficacy, Safety
	Study status	Completed
	Duration of the study	-
	Region	Japan
Contact information	Organization	Toyama Chemical Co., Ltd.
	Division	Clinical Planning Department
	Contact	Form for Inquiry https://www.toyama-chemical.co.jp/en/form/general/input.php?id=TCClinicalEn